Title:
BISDIAZABICYCLO COMPOUND FOR TREATING AND/OR PREVENTING HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS
Document Type and Number:
WIPO Patent Application WO/2019/101047
Kind Code:
A1
Abstract:
Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
Inventors:
ZHAI YIFAN (CN)
ZHANG XIAOYONG (CN)
HOU JINLIN (CN)
YANG DAJUN (CN)
ZHANG XIAOYONG (CN)
HOU JINLIN (CN)
YANG DAJUN (CN)
Application Number:
PCT/CN2018/116289
Publication Date:
May 31, 2019
Filing Date:
November 20, 2018
Export Citation:
Assignee:
JIANGSU ASCENTAGE BIOMED DEV INC (CN)
HEALTHQUEST PHARMA INC (CN)
HEALTHQUEST PHARMA INC (CN)
International Classes:
C07D487/04; A61K31/407; A61P1/16; A61P29/00; A61P31/14; A61P31/20; C07D519/00
Domestic Patent References:
| WO2016172134A2 | 2016-10-27 | |||
| WO2015109391A1 | 2015-07-30 | |||
| WO2011050068A2 | 2011-04-28 | |||
| WO2014031487A1 | 2014-02-27 |
Foreign References:
| CN104718209A | 2015-06-17 | |||
| CN102378762A | 2012-03-14 | |||
| CN101484151A | 2009-07-15 | |||
| CN107987083A | 2018-05-04 | |||
| US7960372B2 | 2011-06-14 | |||
| US20050197403A1 | 2005-09-08 | |||
| US20130055384W | 2013-08-16 |
Other References:
SHENG, RONG ET AL.: "A Potent Bivalent Smac Mimetic (SM-1200) Achieving Rapid, Complete, and Durable Tumor Regression in Mice", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 7 May 2013 (2013-05-07), pages 3969 - 3979, XP055504669, DOI: doi:10.1021/jm400216d
BERTOLETTI, A.C. FERRARI: "Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection", GUT, vol. 61, no. 12, 2012, pages 1754 - 1764
CHOU, HHWH CHIENLL WUCH CHENGCH CHUNGJH HORNGYH NIHT TSENGD. WUX. LU: "Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota", PROC NATL ACAD SCI USA, vol. 112, no. 7, 2015, pages 2175 - 2180
"J Hepatol", vol. 57, 2012, EUROPEAN ASSOCIATION FOR THE STUDY OF THE, L., article "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", pages: 167 - 185
GISH, RGBD GIVENC.-L. LAISA LOCARNINIJYN LAUDL LEWIST. SCHLUEP: "Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities", ANTIVIRAL RESEARCH, vol. 121, 2015, pages 47 - 58, XP029256090, DOI: 10.1016/j.antiviral.2015.06.008
GUIDOTTI, LGD. INVERSOL. SIRONIP. DI LUCIAJ. FIORAVANTIL. GANZERA. FIOCCHIM. VACCAR. AIOLFIS. SAMMICHELI: "Immunosurveillance of the liver by intravascular effector CD8 (+) T cells", CELL, vol. 161, no. 3, 2015, pages 486 - 500
GUIDOTTI, L. G.R. ROCHFORDJ. CHUNGM. SHAPIROR. PURCELLF. V. CHISARI: "Viral clearance without destruction of infected cells during acute HBV infection", SCIENCE, vol. 284, no. 5415, 1999, pages 825 - 829
HOH, A.M. HEEGY. NIA. SCHUCHB. BINDERN. HENNECKEHE BLUMM. NASSALU. PROTZERM. HOFMANN: "Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8 + T Cells In Vitro", J VIROL, vol. 89, no. 14, 2015, pages 7433 - 7438
HUANG, L. R.H. L. WUP. J. CHEND. S. CHEN: "An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection", PROC NATL ACAD SCI USA, vol. 103, no. 47, 2006, pages 17862 - 17867
LIAW, YFN. LEUNGJH KAOT. PIRATVISUTHE. GANEKH HANR. GUANGK LAUS. LOCAMINIBGWP OT A.-PA FT S.: "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", HEPATOL INT, vol. 2, no. 3, 2008, pages 263 - 283
LIU, J.HI YANGMH LEESN LUCL JENR. BATRLA-UTERMANNLY WANGSL YOUCK HSIAOPJ CHEN: "Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma", GUT, vol. 63, no. 10, 2014, pages 1648 - 1657
LOK, A. S.B. J. MCMAHON: "Chronic hepatitis B: update 2009", HEPATOLOGY, vol. 50, no. 3, 2009, pages 661 - 662
LUCIFORA, J.C. TREPO: "Hepatitis: After HCV cure, HBV cure?", NAT REV GASTROENTEROL HEPATOL, vol. 12, no. 7, 2015, pages 376 - 378
LUCIFORA, J.Y. XIAF. REISINGERK. ZHANGD. STADLERX. CHENGMF SPRINZLH. KOPPENSTEINERZ. MAKOWSKAT. VOLZ: "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", SCIENCE, vol. 343, no. 6176, 2014, pages 1221 - 1228, XP055564930, DOI: 10.1126/science.1243462
NASSAL, M.: "HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.", GUT, vol. 64, no. 12, 2015, pages 1972 - 1984, XP055592645, DOI: 10.1136/gutjnl-2015-309809
SUNDARAM, V.K. KOWDLEY: "Management of chronic hepatitis B infection", BMJ, vol. 351, 2015, pages h4263
WONG, D. K.W. K. SETOJ. FUNGP. IPF. Y. HUANGC. L. LAIM. F. YUEN: "Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency", CLIN GASTROENTEROL HEPATOL, vol. 11, no. 8, 2013, pages 1004 - 1010
YANG, D.L. LIUD. ZHUH. PENGL. SUY. X. FUL. ZHANG: "A mouse model for HBV immunotolerance and immunotherapy", CELL MOL IMMUNOL, vol. 11, no. 1, 2014, pages 71 - 78
See also references of EP 3715349A4
BERTOLETTI, A.C. FERRARI: "Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection", GUT, vol. 61, no. 12, 2012, pages 1754 - 1764
CHOU, HHWH CHIENLL WUCH CHENGCH CHUNGJH HORNGYH NIHT TSENGD. WUX. LU: "Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota", PROC NATL ACAD SCI USA, vol. 112, no. 7, 2015, pages 2175 - 2180
"J Hepatol", vol. 57, 2012, EUROPEAN ASSOCIATION FOR THE STUDY OF THE, L., article "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", pages: 167 - 185
GISH, RGBD GIVENC.-L. LAISA LOCARNINIJYN LAUDL LEWIST. SCHLUEP: "Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities", ANTIVIRAL RESEARCH, vol. 121, 2015, pages 47 - 58, XP029256090, DOI: 10.1016/j.antiviral.2015.06.008
GUIDOTTI, LGD. INVERSOL. SIRONIP. DI LUCIAJ. FIORAVANTIL. GANZERA. FIOCCHIM. VACCAR. AIOLFIS. SAMMICHELI: "Immunosurveillance of the liver by intravascular effector CD8 (+) T cells", CELL, vol. 161, no. 3, 2015, pages 486 - 500
GUIDOTTI, L. G.R. ROCHFORDJ. CHUNGM. SHAPIROR. PURCELLF. V. CHISARI: "Viral clearance without destruction of infected cells during acute HBV infection", SCIENCE, vol. 284, no. 5415, 1999, pages 825 - 829
HOH, A.M. HEEGY. NIA. SCHUCHB. BINDERN. HENNECKEHE BLUMM. NASSALU. PROTZERM. HOFMANN: "Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8 + T Cells In Vitro", J VIROL, vol. 89, no. 14, 2015, pages 7433 - 7438
HUANG, L. R.H. L. WUP. J. CHEND. S. CHEN: "An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection", PROC NATL ACAD SCI USA, vol. 103, no. 47, 2006, pages 17862 - 17867
LIAW, YFN. LEUNGJH KAOT. PIRATVISUTHE. GANEKH HANR. GUANGK LAUS. LOCAMINIBGWP OT A.-PA FT S.: "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", HEPATOL INT, vol. 2, no. 3, 2008, pages 263 - 283
LIU, J.HI YANGMH LEESN LUCL JENR. BATRLA-UTERMANNLY WANGSL YOUCK HSIAOPJ CHEN: "Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma", GUT, vol. 63, no. 10, 2014, pages 1648 - 1657
LOK, A. S.B. J. MCMAHON: "Chronic hepatitis B: update 2009", HEPATOLOGY, vol. 50, no. 3, 2009, pages 661 - 662
LUCIFORA, J.C. TREPO: "Hepatitis: After HCV cure, HBV cure?", NAT REV GASTROENTEROL HEPATOL, vol. 12, no. 7, 2015, pages 376 - 378
LUCIFORA, J.Y. XIAF. REISINGERK. ZHANGD. STADLERX. CHENGMF SPRINZLH. KOPPENSTEINERZ. MAKOWSKAT. VOLZ: "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", SCIENCE, vol. 343, no. 6176, 2014, pages 1221 - 1228, XP055564930, DOI: 10.1126/science.1243462
NASSAL, M.: "HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.", GUT, vol. 64, no. 12, 2015, pages 1972 - 1984, XP055592645, DOI: 10.1136/gutjnl-2015-309809
SUNDARAM, V.K. KOWDLEY: "Management of chronic hepatitis B infection", BMJ, vol. 351, 2015, pages h4263
WONG, D. K.W. K. SETOJ. FUNGP. IPF. Y. HUANGC. L. LAIM. F. YUEN: "Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency", CLIN GASTROENTEROL HEPATOL, vol. 11, no. 8, 2013, pages 1004 - 1010
YANG, D.L. LIUD. ZHUH. PENGL. SUY. X. FUL. ZHANG: "A mouse model for HBV immunotolerance and immunotherapy", CELL MOL IMMUNOL, vol. 11, no. 1, 2014, pages 71 - 78
See also references of EP 3715349A4
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF:
Previous Patent: METHOD, APPARATUS AND SYSTEM FOR UPLINK PIGGYBACK TRANSMISSION
Next Patent: COMBINATION WASHER DRYER
Next Patent: COMBINATION WASHER DRYER